Humira Market Size & Trends
Global Humira market size was estimated at USD 10.34 billion in 2024 and is forecasted to decline at a CAGR of -11.29% between 2025 and 2030. Market decline mainly results from the growing availability of biosimilars with patent expirations. Regardless of a sustained incidence of autoimmune diseases like rheumatoid arthritis, psoriasis, and Crohn's disease, competition heightens with the entry of affordable substitutes. While pharmaceutical firms keep shelling out money on R&D and geographic expansion and collaborations, pricing pressures and changes in patient preference toward more recent treatments are likely to further affect Humira's market share.
Biosimilar expansion is transforming the Humira marketplace by making it more accessible and affordable. In 2024, the U.S. Food and Drug Administration (FDA) has approved many biosimilars like Amjevita, Hyrimoz, and Yuflyma that have brought strong pricing competition, decreasing treatment prices and increasing patient accessibility. Prescribers and payers are becoming more open to using biosimilars, which is influencing wider adoption of adalimumab in treating autoimmune disease. To counter that, AbbVie has rolled out innovations, including citrate-free products, to continue with product differentiation. The increasing uptake of biosimilars contributes to overall adalimumab use, ensuring market volume irrespective of erosion in prices. Nevertheless, growth in the market slows down even as the rising prevalence of disease translates into long-term demand for biologic treatments such as Humira.
The increasing global incidence of autoimmune diseases continues to act as a structural trend driving the Humira market. A 2023 research article published by The Lancet, on 22 million people, estimated that autoimmune diseases influence one in every ten individuals globally. Increased prevalence is fueled by genetic predisposition, environmental triggers, and better access to healthcare. The Northern European region and North America have a higher prevalence rate due to well-established advanced diagnostics and disease awareness. In emerging markets in Asia, Africa, and Australia, lifestyle change and industrialization are responsible for a steep rise in incidence rates. The growing global pool of autoimmune patients underpins continued demand for biologic therapies like Humira.
The increasing burden of Crohn's disease also contributes to Humira demand. Data from Minnesota indicates that 19% of Crohn’s patients present with complications within 90 days of diagnosis, and 50% develop intestinal complications over 20 years. Crohn’s disease typically affects the ileum, the ileocolonic region, or the colon, with limited migration over time. Humira remains a long-term treatment option across all disease locations. Incidence is greatest among Northern Europeans and Jews, but increasingly markets in Asia, Africa, and Australasia are seeing rising rates because of industrialization. The chronic and progressive course of Crohn's disease reinforces continuous therapeutic demand.
Although Humira is on a declining top-line trajectory with the impact of biosimilar competition and loss of exclusivity, these underlying drivers are maintaining market volumes in stabilizing mode. The worldwide proliferation of autoimmune disease, wider use of biosimilars, and growing prevalence of Crohn's disease underpin demand for adalimumab therapies. Furthermore, biosimilars are opening up new markets by providing biologic treatment at affordable prices. Thus, while market value is in decline, fundamental growth drivers still underpin overall volume of adalimumab use.
Report Coverage & Deliverables
PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Pipeline Analysis
The following analysis outlines key developments in the pipeline for autoimmune and inflammatory conditions, focusing on drugs targeting diseases such as rheumatoid arthritis, ulcerative colitis, and plaque psoriasis. Notable highlights include several promising treatments advancing through Phase 3 trials, including adalimumab for plaque psoriasis and ulcerative colitis, with launches expected between 2027 and 2030. Upadacitinib, aimed at rheumatoid arthritis, and Ixekizumab, for juvenile psoriatic arthritis, also show strong potential, with anticipated launches during the forecast period. The progress across various phases underscores the ongoing innovation in the autoimmune therapeutics market, with several therapies poised to address unmet clinical needs.
Biosimilar Market Growth
The launch of Humira biosimilars is set to transform the autoimmune and inflammatory disease treatment market substantially. In the wake of Humira's patent loss, such biosimilars as Amgen's Amjevita, Samsung Bioepis' Renflexis, and Celltrion's Remsima are presenting 20-30% reduced prices, and thus serve as a desirable substitute for healthcare payers and providers looking to contain costs. This transition lowers healthcare costs and enhances patient access to life-sustaining biologics, especially in cost-sensitive areas. Biosimilars will be anticipated to fuel a more competitive market, pushing pricing pressure on biologic treatments and presenting opportunities in developing markets.
With biosimilars increasingly entering the market, they offer substantial revenue potential for pharma companies. Increasing demand for affordable biologic therapies in various therapeutic categories such as rheumatology, gastroenterology, and oncology fuels the growth of the market. The shift to biosimilars has a particularly powerful effect in those markets with high healthcare expenses and restricted access to biologic therapy, thus positioning biosimilars as an essential solution for enhancing patient access and minimizing healthcare burdens.
In addition, the competition created by biosimilars is driving innovation in pricing models and the creation of new biologic treatments. Firms are incentivized to invest in sophisticated manufacturing technologies to improve production efficiency and address the increasing demand for biologics. As the focus on value-based care continues to grow, biosimilars provide a sustainable way forward by preserving clinical efficacy while providing cost savings, and thus they are an attractive choice for healthcare systems worldwide.
Market Concentration & Characteristics
The Humira market is advancing with innovations driven by the expanding biosimilar landscape. The approval of SIMLANDI (adalimumab-ryvk) introduces a significant leap forward, as it becomes the first high-concentration, citrate-free biosimilar to Humira with FDA-approved interchangeable status. This innovation facilitates pharmacy-level substitution, eliminating the need for prescriber approval, akin to generic drugs. Additionally, SIMLANDI’s citrate-free formulation reduces common injection site reactions, improving patient experience and adherence. These developments are building greater affordability and availability, making biosimilars a game-changer in the biologic marketplace.
The Humira market has a very high level of participation because of difficult biologic drug development hurdles, strict regulatory routes, and AbbVie's highly robust patent portfolio. Biosimilar development entails substantial R&D investment, sophisticated manufacturing capabilities, and large clinical trials to prove similarity in safety and efficacy. Also, the manufacture of monoclonal antibodies such as Humira requires sophisticated processes that are associated with high costs and low replicability. AbbVie's strong established global presence, brand, and long history of relationships with healthcare providers and payers also reinforce its market leadership, rendering it difficult for new entrants to acquire considerable market share rapidly.
Stricter compliance requirements considerably influence the Humira market. Such authorities call for extensive clinical trials and stringent pharmacovigilance for confirming long-term efficacy and safety, particularly because Humira is used to treat such a diverse range of autoimmune conditions. Pricing and reimbursement regulations considerably impact market access due to high-cost treatment, making favorable insurance cover imperative. Regulation harmonization is needed across geographic areas to fuel adoption worldwide, especially in the emerging markets.
Humira is competing with several other biologic therapies and small-molecule drugs, namely in the treatment of autoimmune conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Amjevita, Hadlima, and Hyrimoz biosimilars are cost-effective alternatives, and Enbrel (etanercept), Remicade (infliximab), and Stelara (ustekinumab) biologics are also therapeutic options. Despite this competition, though, Humira's proven efficacy, broad therapeutic use, and unshakeable confidence among doctors maintain its use. Patient comfort, simplicity of administration, and extensive clinical support further establish its grip on the market.
AbbVie has diversified its Humira franchise into emerging markets like Asia-Pacific, Latin America, and Europe, fueled by increasing autoimmune disease incidence and enhancing healthcare infrastructure. For example, Humira is also indicated in Japan for the treatment of intestinal Behçet's disease, generalized pustular psoriasis, and pyoderma gangrenosum. The firm concentrates on gaining regulatory approvals, maximizing pricing approaches, and solidifying reimbursement structures to maximize patient access. Strategic collaborations with healthcare professionals and government programs facilitate market penetration, whereas investments in local manufacturing and distribution networks overcome supply chain issues.
Product Insights
The Humira branded segment led the Humira market in 2024 with 87.0 % share, powered by its strong brand equity, established efficacy, and long-term presence. Since its first approval, Humira has established a strong reputation for use in numerous therapeutic indications such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. Its wide range of uses and extensive clinical trial information have allowed for profound market penetration and broad-based physician and patient confidence. AbbVie has further solidified market leadership through life-cycle management strategies that are strategically aimed at advancing the market, such as the addition of new forms like citrate-free forms and improved auto-injectors for greater patient comfort. For example, Humira continues to be a major driver of the company's immunology business, states AbbVie's Full-Year 2024 fiscal report. In 2024, worldwide Humira net revenues were USD 8.993 billion, while the overall global net revenues from AbbVie's immunology portfolio were USD 26.682 billion. This means Humira has represented about 33.7% of AbbVie's overall immunology revenue for the year.
Biosimilar products are expected to develop at the highest rate in the Humira market due to cost-effectiveness, regulatory approvals, and growing acceptance by healthcare providers and patients. With the patent expiration of Humira in key markets, biosimilars like Amjevita (Amgen) and Hyrimoz (Sandoz) have picked up steam. For instance, in April 2024, Evernorth Health Services launched a program to offer a Humira biosimilar at zero out-of-pocket cost for qualifying patients through its specialty pharmacy, Accredo. Financed by Quallent Pharmaceuticals, Evernorth's private-label partner, the program is facilitated by arrangements with more than one manufacturer of both high- and low-concentration interchangeable biosimilars.
Application Insights
Rheumatoid arthritis (RA) represented 20.5% of Humira market share in 2024. "Global, regional, and national burden of rheumatoid arthritis, 1990-2020," an article published in The Lancet Rheumatology, estimates global RA prevalence, mortality, and DALYs from 1990 to 2020 and projects through 2050. In 2020, there were 17.6 million individuals with RA, representing a 14.1% increase in age-standardized global prevalence compared with 1990. Mortality due to RA fell by 23.8%, whereas DALYs, driven largely by years lived with disability, rose. RA cases are expected to grow to 31.7 million by 2050, underscoring the increasing demand for early diagnosis and access to treatment.
The Ulcerative Colitis (UC) disease segment is expected to see moderate growth in the Humira market, spurred by the increasing incidence of inflammatory bowel diseases (IBD), especially in North America and Northern Europe. These areas have the world's highest incidence and prevalence rates of IBD, which indicate the increasing demand for successful biologic treatments. UC impacts 156 to 291 people out of every 100,000 and has an annual incidence rate of 9 to 20 per 100,000 persons. It has a bimodal age distribution, with a peak onset of 15-30 years and a smaller secondary peak of 50-70 years, highlighting the long-term therapeutic requirements of a heterogeneous patient population. Although UC has no strong gender predilection, it is more frequently seen in non-smokers and recent quitters.
Distribution Channel Insights
Hospital pharmacies led the market and accounted for a share of 41.0% in 2024, driven by the increasing prevalence of diseases that require specialist oversight typically available in hospital settings. Hospitals provide comprehensive care, ensuring patients receive timely and coordinated treatment, which is crucial for biologic therapies like Humira. Hospitals maintain strong, well-coordinated supply chain networks through long-standing partnerships with pharmaceutical manufacturers and distributors. These integrated systems help ensure a reliable and uninterrupted supply of Humira, enabling consistent access for patients who rely on the medication for chronic autoimmune conditions. This streamlined logistics framework reduces the risk of stock shortages and delays in treatment delivery. Their infrastructure and trained staff support the proper storage, temperature control, and handling protocols required for drugs like Humira, ensuring adherence to safety and quality regulations throughout the supply process.
Online pharmacies are experiencing the significant growth in the Humira market due to increasing consumer preference for digital healthcare solutions, driven by technological advancements and changing consumer preferences. Enhanced telemedicine services and direct-to-consumer sales models have further accelerated adoption. Regulatory approvals for online prescription fulfillment and expanding insurance coverage contribute to market penetration. While retail pharmacies remain dominant, online platforms benefit from accessibility, competitive pricing, and discreet purchasing options, positioning them as the fastest-growing distribution channel for Humira-based therapies.
Regional Insights
North America's Humira market is a market leader in 2024 with a global share of 85.7%. The market is supported by positive reimbursement policies, growing awareness of weight management, and an upsurge in off-label prescriptions. The U.S. leads the pack because of stringent pharmaceutical regulations, high patient activation, and strong investments in autoimmune drugs. The market is also driven by constant clinical developments, such as oral Humira treatments. With ongoing regulatory supervision and increasing availability of treatment, North America is still the largest market for Humira-related treatments.
U.S. Humira Market Trends
The U.S. has a monopoly in the Humira market in North America. This is attributed to a high prevalence of autoimmune diseases and robust healthcare infrastructure. For example, as per the Report of the Office of Autoimmune Disease Research by NIH, Autoimmune diseases are estimated to occur in 7% to 8% of the United States population, with over 23.5 million Americans suffering from autoimmune diseases. Early regulatory clearances and high R&D efforts are driving market growth. Increased use of Humima for chronic conditions is changing prescribing patterns.
Europe Humira Market Trends
Europe shows consistent Humira market expansion, led by Germany, France, and the UK. The region is favored by rising biosimilar uptake after patent expiration, new EMA guidelines on immunomodulators, and focus on pharmacoeconomics. National health services encourage switch programs to contain costs, as local companies are increasing biosimilar manufacturing capacity.
The UK Humira market is growing because of NHS-supported biosimilar launch programs and individualized treatment routes for chronic inflammatory conditions. For example, in January 2024, the UK government launched the 2024 Voluntary Scheme for Branded Medicines Pricing and Access (VPAG), a USD 500 million collaborative program with the pharmaceutical sector. It is supporting clinical trials, health technology assessment, and production, with the aim to increase access to biosimilars and personalized treatments. Government grants for biopharmaceutical R&D and speedier approval tracks for biosimilars are increasing market competition. The importance of community pharmacy in dispensing biosimilars is growing as well.
The Germany Humira market ranks first in the Europe market based on its developed biopharmaceutical production capabilities and strong healthcare system. Hospital formularies have been designed to incorporate budget-friendly biosimilar alternatives, helped by government subsidies and electronic prescribing systems that streamline biologic drugs.
The France Humira market is experiencing swift growth, fueled by increasing incidence of inflammatory bowel disease. Based on NIH 2024 epidemiology statistics, in France, a total of 22,879 new cases of inflammatory bowel disease (IBD) were reported during the study period, of which 59% were Crohn's disease, 38% ulcerative colitis, and 3% unclassified IBD. The overall rates of incidence were 12.7 per 100,000 individuals per annum for IBD, 7.2 for CD, and 5.1 for UC. Importantly, the incidence of Crohn's disease increased from 5.1 during 1988-1990 to 7.9 during 2015-2017, with an average annual increase rate of 1.9%. Cases of ulcerative colitis went up from 4.5 to 6.1, with an annual increase rate of 1.3%. This pattern of disease incidence highlights the expanding need for potent biologic drugs such as Humira, making France a major market for future investment and therapeutic development.
Asia Pacific Humira Market Trends
The Asia-Pacific market for Humira is growing strongly, fueled by rising access to biologics, government subsidies for the treatment of chronic disease, and intensifying collaborations with multination biopharma organizations. For example, in October 2024, delegates from several Asia-Pacific countries officially embraced strategic frameworks regarding health financing and digital health as part of an overall drive to pursue universal health coverage. These efforts, which are endorsed by the World Health Organization (WHO), aim to make public healthcare spending more efficient and raise the standing of digital technologies in disease management in the case of chronic illnesses. Hospital Humira uptake is on the rise across the region.
The Japanese market for Humira is growing as a result of efforts like the "Healthy Aging" policy that focuses on control of chronic diseases in the aged. Outpatient therapy is seeing more use of biologics, and domestic drug companies are launching biosimilar products suitable for the Japanese market. Online health platforms are also facilitating improved monitoring of treatment.
The China Humira market is quickly positioning itself as a biosimilar giant, due to government policies promoting fast-track approval and price regulation of biologics. Humira biosimilars are covered under public insurance programs, while hospital-private sector alliances and e-commerce health platforms boost distribution.
Latin America Humira Market Trends
Latin America demonstrates moderate but consistent growth, with Brazil and Argentina in the lead. Penetration of biosimilars is growing owing to economic limitations and new public health procurement policies. Partnerships with international pharma companies are assisting local players in scaling up production and enhancing quality standards.
The Brazilian Humira market is growing in the face of high autoimmune disease incidence and biosimilar adoption support. The government has given priority to chronic disease therapy under the SUS (Unified Health System), increasing availability in public hospitals. Local manufacturing and foreign licensing agreements are also pushing market availability.
Middle East & Africa Humira Market Trends
Saudi Arabia and the UAE are the emerging markets for Humira in the Middle East and Africa. Biologics infrastructure is supported through government initiatives such as Vision 2030 (Saudi Arabia) and digitalization of healthcare (UAE). The distributors are more and more joining hands with international biosimilar manufacturers to enhance affordability and access.
The Saudi Humira market is growing as a result of high biopharma investments and increasing rates of autoimmune and metabolic conditions. Government subsidies and health insurance reforms are enabling biosimilar adoption. Telemedicine services and e-pharmacy platforms are expanding coverage in urban and rural regions.
Key Humira Company Insights
Humira's market has passed into an era of accelerated transformation after the loss of exclusivity for the drug in the major markets around the world. During 2024, competitive pressure has increased significantly, with a cluster of biosimilars gaining approvals at regulatory levels and launching in different geographies. This process is hugely changing the dynamics of competition by reducing the cost of treatment for healthcare systems and enhancing patient accessibility for autoimmune and inflammatory diseases.
New players in the biosimilar space are utilizing innovative tactics, such as high-concentration, citrate-free products and interchangeability approvals, to differentiate their products. Companies are also creating strategic partnerships with multinational pharma companies to use established manufacturing infrastructure, global supply chains, and in-market capabilities. All this is adding up to a more diversified and available biologics market globally.
Key Humira Companies
The following are the leading companies in the humira market. These companies collectively hold the largest market share and dictate industry trends.
- Alvotech
- Amgen Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- CELLTRION INC.
- Coherus BioSciences, Inc.
- Fresenius Kabi AG
- FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
- Pfizer Inc.
- Samsung Bioepis
- Sandoz Inc.
Recent Developments
-
In April 2025, the U.S. Food and Drug Administration granted interchangeable status to YUFLYMA, a high-strength, citrate-free biosimilar to Humira, which is manufactured by Celltrion, Inc. The status pertains to multiple inflammatory conditions and enables substitution of YUFLYMA for Humira by pharmacists without a new prescription.
In October 2024, Prime Therapeutics unveiled new biosimilar initiatives to increase access to affordable Humira alternatives. Beginning in 2025, Prime will suggest four manufacturers' biosimilarsOrganon (Hadlima), Teva (Simlandi), Sandoz (adalimumab-adaz), and Celltrion (adalimumab-aaty) with flexible plan options such as biosimilars-first or biosimilars-only plans. These include low-list-price biosimilars with net monthly prices ranging as low as USD 500-USD 600. They are facilitated by Prime's conflict-free specialty pharmacy network to assist in providing wider access and affordability to millions of Americans.
In December 2023, Biocon Biologics Ltd. (BBL), the subsidiary of Biocon and a global biosimilars player, signed a strategic distribution partnership with Sandoz. Pursuant to this partnership, Sandoz received exclusive rights to market, distribute, and sell Adalimumab BS for subcutaneous injection (a biosimilar to Humira) in Japan.
Humira Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 7.48 billion |
|
Revenue forecast in 2030 |
USD 4.11 billion |
|
Growth rate |
CAGR of -11.29% from 2025 to 2035 |
|
Base year for estimation |
2024 |
|
Historical data |
2018 - 2023 |
|
Forecast period |
2025 - 2035 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2035 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
|
Segments covered |
Product, application, distribution channel, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
AbbVie, Alvotech, Amgen Inc., Boehringer Ingelheim Pharmaceuticals Inc., Celltrion Inc., Coherus Biosciences Inc., Fresenius Kabi AG, Fujifilm Kyowa Kirin Biologics Co., Ltd., Pfizer Inc., Samsung Bioepis, and Sandoz Inc. |
|
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
Global Humira Market Report Segmentation
Product Outlook (Revenue, USD Million; 2018 - 2030)
-
-
Branded
-
Biosimilar
-
-
Application Outlook (Revenue, USD Million; 2018 - 2035)
-
Rheumatoid Arthritis (RA)
-
Psoriatic Arthritis (PsA)
-
Crohn’s Disease (CD)
-
Ulcerative Colitis (UC)
-
Ankylosing Spondylitis
-
Others
-
-
Distribution Channel Outlook (Revenue, USD Million; 2018 - 2035)
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
-
Regional Outlook (Revenue, USD Million; 2018 - 2035)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
South Korea
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy